News
Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback